CoChat

Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?

Open access
Molinari, Chiara, Marisi, Giorgia, Passardi, Alessandro, Matteucci, Laura, De Maio, Giulia, Ulivi, Paola · 2018 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Abstract

High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results can occur, leading to non optimal therapy. Moreover, temporal molecular heterogeneity during treatment is known to influence the response to therapy and prognosis. We present a literature overview of advances made in characterizing molecular heterogeneity in CRC, underlining that the analysis of liquid biopsy could represent an efficient non-invasive tool to overcome the problem. We believe that understanding CRC heterogeneity is fundamental for a more accurate diagnosis, for selecting the best targets to ensure prolonged antitumor response, and for monitoring minimal residual disease and the onset of resistance to therapy, all essential components of successful personalized treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms19123733

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the main types of heterogeneity in colorectal cancer (CRC), and the central role of liquid biopsy.
Figure 1 Overview of the main types of heterogeneity in colorectal cancer (CRC), and the central role of liquid biopsy.CC BY · PubMed Central
Figure 2 Spatio-temporal heterogeneity and the role of liquid biopsy in the management of mCRC. Example based on RAS mutational status analysis. (a) RAS wild type (wt) tumors. Even in an apparently homogeneous genetic context, the selective pressure exerted by drugs can induce de novo mutations or the selection of mutations present at subclonal level in the primary tumor. (b) RAS mutated tumors. Heterogeneity can be present within the primary tumor, within metastases, and between primary tumor and metastases. Treatment based on chemotherapy + anti-angiogenic drugs can determine a switch to prevalently wt RAS circulating tumor DNA (ctDNA).
Figure 2 Spatio-temporal heterogeneity and the role of liquid biopsy in the management of mCRC. Example based on RAS mutational status analysis. (a) RAS wild type (wt) tumors. Even in an apparently homogeneous genetic context, the selective pressure exerted by drugs can induce de novo mutations or the selection of mutations present at subclonal level in the primary tumor. (b) RAS mutated tumors. Heterogeneity can be present within the primary tumor, within metastases, and between primary tumor and metastases. Treatment based on chemotherapy + anti-angiogenic drugs can determine a switch to prevalently wt RAS circulating tumor DNA (ctDNA).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 116 references

Cited by

Items 201–272 of 272

Metadata

Authors
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P.
Affiliations
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
Corresponding author
Ulivi, Paola
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2018-11-23
Volume
19
Issue
12
Pages
3733
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2901481287
Cited by
262
References
116
Citations by year
2026: 21 · 2025: 24 · 2024: 30 · 2023: 25 · 2022: 84 · 2021: 49 · 2020: 20 · 2019: 9
FWCI
2.04
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, tumor heterogeneity, spatial heterogeneity, interpatient variability, metastatic colorectal cancer, anti-EGFR monoclonal antibody, liquid biopsy, minimal residual disease, treatment resistance, personalized medicine, molecular characterization
MeSH terms
Liquid Biopsy, Biological Variation, Individual, Humans, Neoplasm Metastasis, Neoplasm Staging, Biomarkers, Tumor, Colorectal Neoplasms, Genetic Heterogeneity, Molecular Diagnostic Techniques, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.